2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 103

Identification of IL-17+ and IL-10+ TCRαβ+ CD4- CD8- double Negative (DN) T Cell Subsets in Lupus-Prone Mice and Patients with SLE and Their Significance in Predicting Renal Involvement
Abstract Number: 104

Identification of a Gut Pathobiont Immunostimulatory Lipoglycan Antigen Linked to Lupus Nephritis
Abstract Number: 105

Immunologic Properties of Cutaneous Lupus Erythematosus (CLE) Patients Refractory to Antimalarials Compared to Patients That Respond to Antimalarials
Abstract Number: 106

Highly Elevated Levels of Anti-Mitochondrial Antibodies in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 107

Apolipoprotein L1 Risk Variants, Renal Histopathology, and Prognosis in African American SLE Nephritis Patients: A Cohort Study
Abstract Number: 108

Sex-Specific Expression of CXorf21 Provide Molecular Explanation for the Fundamental Difference in Male and Female Immune Response: An Explanation for Female-Bias SLE Pathogenesis
Abstract Number: 109

Unique miRNA Signatures Detected in Extracellular Vesicles from Patients with Systemic Lupus Erythematous
Abstract Number: 110

Single-Cell RNA-Seq Analysis of ANA+ Healthy and SLE Patients Show Variations in Activated Stress Response and Regulatory Pathways
Abstract Number: 111

BAFF Inhibition Attenuates Fibrosis in Bleomycin-Induced Scleroderma Model Via Modulating the Regulatory and Effector B-Cell Balance
Abstract Number: 112

Evidence for Altered Peroxisome Proliferator Activated Receptor (PPAR) Pathway Activity in a Transgenic Mouse Model of Scleroderma (TβRIIΔk-fib): Analysis of Mouse Skin, Lung and Explanted Cells
Abstract Number: 113

Epigenetic Changes in Dermal Fibroblasts By Inhibition of DOT1L Affect Cell Proliferation and Cell Cycle, but Have No Direct Effects on Collagen Deposition in in Vitro and In Vivo models of Fibrosis
Abstract Number: 114

Antifibrotic Regulation By Response Gene to Complement 32 Protein
Abstract Number: 115

CTLA4-Ig/CD86 Interaction on Cultered Human Fibrocytes and Fibroblasts from Systemic Sclerosis Patients
Abstract Number: 116

Identifying Matricellular Protein CYR61 As a Potential Anti-Fibrotic and Pro-Angiogenic Mediator in Scleroderma
Abstract Number: 117

Hypomorphic A20 Expression Modulates Fibrosis Susceptibility: Implications for Systemic Sclerosis?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].